Literature DB >> 26491056

Potential Biases Introduced by Conflating Screening and Diagnostic Testing in Colorectal Cancer Screening Surveillance.

Elizabeth A Becker1, Derek M Griffith2, Brady T West3, Nancy K Janz4, Ken Resnicow4, Arden M Morris5.   

Abstract

BACKGROUND: Screening and postsymptomatic diagnostic testing are often conflated in cancer screening surveillance research. We examined the error in estimated colorectal cancer screening prevalence due to the conflation of screening and diagnostic testing.
METHODS: Using data from the 2008 National Health Interview Survey, we compared weighted prevalence estimates of the use of all testing (screening and diagnostic) and screening in at-risk adults and calculated the overestimation of screening prevalence across sociodemographic groups.
RESULTS: The population screening prevalence was overestimated by 23.3%, and the level of overestimation varied widely across sociodemographic groups (median, 22.6%; mean, 24.8%). The highest levels of overestimation were in non-Hispanic white females (27.4%), adults ages 50-54 years (32.0%), and those with the highest socioeconomic vulnerability [low educational attainment (31.3%), low poverty ratio (32.5%), no usual source of health care (54.4%), and not insured (51.6%); all P < 0.001].
CONCLUSIONS: When the impetus for testing was not included, colorectal cancer screening prevalence was overestimated, and patterns of overestimation often aligned with social and economic vulnerability. These results are of concern to researchers who use survey data from the Behavioral Risk Factor Surveillance System (BRFSS) to assess cancer screening behaviors, as it is currently not designed to distinguish diagnostic testing from screening. IMPACT: Surveillance research in cancer screening that does not consider the impetus for testing risks measurement error of screening prevalence, impeding progress toward improving population health. Ultimately, to craft relevant screening benchmarks and interventions, we must look beyond "what" and "when" and include "why." ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26491056      PMCID: PMC4670579          DOI: 10.1158/1055-9965.EPI-15-0359

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

1.  Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys.

Authors:  N Breen; D K Wagener; M L Brown; W W Davis; R Ballard-Barbash
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

Review 2.  Adherence with colorectal cancer screening guidelines: a review.

Authors:  Sujha Subramanian; Michelle Klosterman; Mayur M Amonkar; Timothy L Hunt
Journal:  Prev Med       Date:  2004-05       Impact factor: 4.018

3.  Socioeconomic and physician supply determinants of racial disparities in colorectal cancer screening.

Authors:  Samir Soneji; Katrina Armstrong; David A Asch
Journal:  J Oncol Pract       Date:  2012-07-03       Impact factor: 3.840

4.  Vital signs: colorectal cancer screening among adults aged 50-75 years - United States, 2008.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-07-09       Impact factor: 17.586

5.  Validity of self-reported colorectal cancer screening behavior.

Authors:  M Baier; N Calonge; G Cutter; M McClatchey; S Schoentgen; S Hines; A Marcus; D Ahnen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-02       Impact factor: 4.254

6.  Prevalence of colorectal cancer screening among adults--Behavioral Risk Factor Surveillance System, United States, 2010.

Authors:  Djenaba A Joseph; Jessica B King; Jacqueline W Miller; Lisa C Richardson
Journal:  MMWR Suppl       Date:  2012-06-15

7.  Patterns of colorectal cancer screening uptake among men and women in the United States.

Authors:  Helen I Meissner; Nancy Breen; Carrie N Klabunde; Sally W Vernon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-02       Impact factor: 4.254

  7 in total
  2 in total

1.  Society of Behavioral Medicine (SBM) position statement: SBM supports the National Colorectal Cancer Roundtable's (NCCRT) call to action to reach 80 % colorectal cancer screening rates by 2018.

Authors:  Elizabeth A Becker; Joanna Buscemi; Marian L Fitzgibbon; Karriem Watson; Kameron L Matthews; Robert A Winn
Journal:  Transl Behav Med       Date:  2016-06       Impact factor: 3.046

2.  Conflating Colorectal Cancer Screening and Diagnostic Testing-Letter.

Authors:  Thomas M Atkinson; Talya Salz; Jennifer L Hay
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-08       Impact factor: 4.254

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.